Novo Nordisk Us - Search News

Novo Nordisk’s Ozempic Gets FDA Approval

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

Bloomberg on MSN · 6h

Novo’s Ozempic Gains US Nod for Kidney Disease, Widening Use

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.

Pharmaceutical Technology · 3h

Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD

The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D and CKD. Novo Nordisk said its drug is the “most broadly indicated” GLP-1RA in its class.

1d

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

The giant US stocks this Alpha Manager is shorting

News archive including articles on Fund Managers, Fund Selection, Asset Allocation, Absolute Return, Offshore Investments, ...

Outsourcing-pharma1d

Novo Nordisk’s next-generation obesity drug shows promise in early clinical trials

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results